Toxicology Resources > For Medical Professionals > ACMT Position Statements and Guidelines

ACMT Positions, Guidelines and Recommendations

ACMT Position Statements

 Interpretation of Urine for Tetrahydrocannabinol Metabolites by Kristen Malecki, posted on 12:36 PM, November 21, 2019
 Recommending Removing The Waiver Requirement For Prescribing Buprenorphine For Opioid Use Disorder by Kristen Malecki, posted on 11:20 AM, July 11, 2019
 Addressing Pediatric Cannabis Exposure posted on 1:54 PM, April 3, 2019
 Buprenorphine Administration in the Emergency Department by Kristen Malecki, posted on 8:07 AM, December 14, 2018
 Addressing the Rising Cost of Prescription Antidotes by Kristen Malecki, posted on 10:12 AM, January 22, 2018
 Alternative or Contingency Countermeasures for Acetylcholinesterase Inhibiting Agents by Kristen Malecki, posted on 10:32 AM, November 29, 2017
 The​ ​Role​ ​of​ ​Clinical​ ​Pharmacists​ ​in​ ​the​ ​Emergency​ ​Department by Kristen Malecki, posted on 11:34 AM, August 23, 2017
 Sodium Bicarbonate Shortage Recommendations posted on 12:53 PM, August 22, 2017
 Preventing Occupational Fentanyl and Fentanyl Analog Exposure to Emergency Responders by Kristen Malecki, posted on 10:29 AM, July 13, 2017
 Safety Data Sheets by ACMT National Office, posted on 12:49 PM, June 1, 2017
 Determining Brain Death in Adults After Drug Overdose by Tara Frutkin, posted on 9:46 AM, March 8, 2017
 Duration of Intravenous Acetylcysteine Therapy Following Acetaminophen Overdose by Tara Frutkin, posted on 12:55 PM, May 3, 2016
 Safety Issues Regarding Prescription Fentanyl Products by Tara Frutkin, posted on 12:54 PM, May 3, 2016
 The Use of Methadone as an Analgesic by Tara Frutkin, posted on 12:52 PM, May 3, 2016
 Safety Issues Regarding Prescription Opioids by Tara Frutkin, posted on 12:31 PM, May 3, 2016
 ACMT Ethics Statement by Tara Frutkin, posted on 11:06 AM, May 3, 2016
 Guidance Document: Management Priorities in Salicylate Toxicity by ACMT National Office, posted on 8:51 AM, June 18, 2013
 Medical Toxicologist Participation in Medication Management and Safety Systems by ACMT National Office, posted on 10:36 AM, February 5, 2013
 Antidote Shortages: Impact and Response by ACMT National Office, posted on 1:12 PM, November 19, 2012
 Pressure Immobilization After North American Crotalinae Snake Envenomation by ACMT National Office, posted on 1:59 PM, August 14, 2012
 The Role of a Medical Toxicologist for Assistance in the Treatment of Alcohol Withdrawal Syndrome by ACMT National Office, posted on 12:56 PM, August 14, 2012
 Interpretation of Urine Analysis for Cocaine Metabolites by ACMT National Office, posted on 9:17 AM, August 14, 2012
 Institutions Housing Venomous Animals by ACMT National Office, posted on 9:13 AM, August 14, 2012
 Recognition of Medical Direction and Support of Poison Center Activities by ACMT National Office, posted on 7:29 AM, October 15, 2010
 Interim Guidance for the Use of Lipid Resuscitation Therapy by ACMT National Office, posted on 7:12 AM, October 15, 2010
 American College of Medical Toxicology Code of Ethics for Medical Toxicologists by ACMT National Office, posted on 12:09 PM, March 31, 2010
 Post-Chelator Challenge Urinary Metal Testing by Nathan Charlton, MD and Kevin L. Wallace, MD FACMT, posted on 10:35 AM, July 27, 2009
 Dietary Supplements by Thomas L. Kurt, M.D., MPH, Dallas TX, posted on 3:35 PM, December 9, 2008
 IOM Report on Thimerosal and Autism by Thomas L. Kurt, M.D., MPH, Dallas TX, posted on 10:02 PM, August 30, 2007
 Hospital Privileges for Physicians Practicing Medical Toxicology posted on 9:46 PM, August 30, 2007
 Institute of Medicine Report on Damp Indoor Spaces and Health by Thomas L. Kurt, M.D., MPH, Dallas TX and Daniel L. Sudakin, M.D., MPH, Corvalis OR, posted on 10:01 PM, June 30, 2006
RSS rss
 
 
These statements are intended to summarize a vast body of reviewed literature and expert opinion in a 1-2 page document with a small number (8-10) of references. The intended audience is both college members and others interested in the given topic. We see these as providing the basis for response to media, patients, and the starting point for further reading. They are not intended to be exhaustive treatises; however they should recognize areas of controversy, providing a position backed by legitimate science. When applicable, each statement should include: * Introduction Introduce the topic or controversy and provide background regarding context (of exposure, contact, etc.) and purpose. * Data Where appropriate, this should be broken out into basic science, animal, human (epidemiologic, case-control, anecdotal) components. While raw numbers and summaries of studies are not required, any relative risk data should be referenced. * Conclusions Brief statement summarizing position of College. While not required, it is encouraged that authors use terms of the Bradford Hill criteria whenever imputing or refuting causation issues (strength of association, specificity, dose response, temporality, coherence, consistency, etc.). * References Major reviews and critiques. Any specific data cited in the statement should be referenced by author in the body of the statement. * Date Include the date of submission (month/year) and any revisions noted.

All position statements will be edited by the committee and then referred to the board. Any comments will be reviewed by the authors and the committee. Once endorsed by the board, they will be posted on the ACMT web site and published in an issue of JMT. All position statements will be introduced by a disclaimer indicating that while individual practitioners may differ, this is the position of the college at the time written, after a review of the issue and pertinent literature. All statements should be reviewed on a periodic basis (every 3 years) and as needed when new data or questions arise. The original author(s) will be asked to address any questions, indicating the date of any revisions on the statement. Each author must sign a disclosure form discussing any potential sources of bias and conflict of interest.